To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Inclusion Criteria:

1. Understand the purpose and risks of the study and provide informed consent inaccordance with national and local privacy laws:

2. Subject must be male, aged >18 years old at the time of signing informed consent,and ≤65 years old:

3. Participants with confirmed hemophilia A in their pre-admission history and based onclinical laboratory examination ;

4. Subjects had used FVII products for at least 150 exposure days (ED) beforeenrollment;

5. Subject has no prior history of FVIII inhibitors;

6. Subjects agree to use a reliable barrier contraceptive method from the date ofsigning the informed consent

7. Subject is willing and able to follow planned visits, treatment plans, and otherstudy procedures.

Exclusion Criteria:

1. The subject has any hemorrhagic disorder not related to hemophilia A,

2. Abnormal liver function test results of subjects during screening.

3. Abnormal laboratory examination of subjects during screening

4. The subject has acute or chronic hepatitis B virus (HBV) infection or chronichepatitis C virus (HCV) infection; Or are receiving antiviral treatment forhepatitis B and C;

5. Active systemic immune disease.